Elevidys (delandistrogene moxeparvovec) for a Saudi family: what the pathway looks like in 2026
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
A Saudi family of a son with Duchenne muscular dystrophy walks into this decision with more than a treatment question. There is a clinical question, a regulatory question, a financial one, and a family one, and they all need answers in roughly the same week. This page is meant to be the first honest read you get on Elevidys in the Kingdom of Saudi Arabia, written by the team that would coordinate it for your son if you decided to go forward. We assume your paediatric neurologist has either raised it with you or you have raised it with them.
We will be specific about what changed in 2025 about who Elevidys is currently approved for, what the workup decides, what it costs in SAR and US dollars, where the infusion can be given in the Kingdom (or via international referral), and what life looks like in the six months after.
What changed in 2025, and what it means for your son
In June 2025, after two fatal acute liver failure events in non-ambulatory patients who had been treated with Elevidys, Sarepta voluntarily paused distribution for non-ambulatory boys. In July 2025, after a third death from acute liver failure, the FDA placed Elevidys on a brief clinical hold, lifted on 28 July 2025 with a new boxed warning, the strongest warning the FDA issues, and a narrowed approved indication. As of 2026, the FDA-approved indication for Elevidys is ambulatory boys aged 4 and older with a genetically confirmed DMD mutation. Non-ambulatory patients are not currently treated outside of specific trial settings, and the manufacturer's qualified-centre network internationally mirrors that restriction.
If your son is still walking, even imperfectly, you are inside the current indication and the rest of this page is directly relevant. If your son has lost ambulation, Elevidys is not currently the right answer, but there are other paths that may be, and we'd like to talk those through with you. Exon-skipping therapies for eligible mutations (Exondys 51 for exon 51, Vyondys 53 and Viltepso for exon 53, Amondys 45 for exon 45, depending on the specific mutation), supportive-care optimisation, and emerging therapies in late-stage development each have a place for different patient subgroups. Reach out and we will walk through your son's specific picture before drawing any conclusions.
The under-4 group is also outside the current approved indication. Families often ask about waiting until age 4. The answer your paediatric neurologist will give is that the window is age- and stage-sensitive. The benefit of the therapy is highest when there is still dystrophin-producing muscle mass to preserve. Time matters, and the right consultation timing is now, even if the infusion timing is later.
What Elevidys actually is, in plain terms
Elevidys is a single intravenous infusion. The active ingredient is an adeno-associated virus, type rh74, engineered to carry a shortened version of the dystrophin gene called micro-dystrophin. Once infused, the virus delivers that gene to muscle cells, which begin producing a shorter, partially functional version of dystrophin protein. The native DMD gene is too large to package into the virus, which is why the therapy uses a shortened construct designed by Sarepta in collaboration with the Nationwide Children's Hospital team that originated this approach.
What Elevidys is not is a cure. The clinical data describe a disease-modifying therapy: a slowing of functional decline against the natural history of DMD, with variability across patients. Your neurologist will walk you through the most recent functional data, including the EMBARK study and the long-term follow-up cohorts. We do not put numbers in marketing form on this page because the honest comparison for your family is your son's current North Star Ambulatory Assessment score against the patient subgroups in the published data, not an averaged headline number.
The workup that decides eligibility
Before any of the rest of the pathway opens, three results need to land.
First, genetic confirmation of a DMD-causing mutation. If your son has already been genetically tested, your neurologist will pull the report; if not, this is the first appointment. Whole-gene sequencing or MLPA-confirmed mutation detection is the standard. The pathology must be consistent with the FDA-approved label. KFSHRC's genetics service in Riyadh has run the Saudi reference cohort for DMD mutations and is the natural setting for this step.
Second, anti-AAVrh74 antibody serology. A meaningful fraction of children have pre-existing antibodies to the AAVrh74 viral vector from prior environmental exposure. A positive titre is a contraindication. The test is run by reference laboratories and typically returns in 7 to 10 days.
Third, baseline hepatic and cardiac function. The 2025 boxed warning makes this non-negotiable. Active hepatitis, elevated transaminases, prior liver injury, and concurrent hepatotoxic medications all need to be assessed and, where present, addressed before the infusion is scheduled. Cardiac MRI baseline is also part of most centres' protocols even though DMD cardiomyopathy presents later in the disease course.
A clinical rationale letter from your neurologist will document all three findings, the North Star score and other functional baselines, the rehabilitation plan, and the requested treatment.
The Saudi regulatory pathway: how it actually works in 2026
The Saudi Food and Drug Authority published its Gene Therapy Products Registration Guidelines in 2023, which gave the kingdom a standardised framework for ATMP evaluation. SFDA has been actively reviewing cell and gene therapy applications since.
A point worth being direct about: as of 2026, Elevidys is not on the SFDA registration list. The therapy has been formally approved by the regulators in the UAE, Qatar, Bahrain, Kuwait, and Oman, but Saudi approval has not yet been granted at the time of writing. This means Saudi-based families currently require the SFDA named-patient mechanism for access, rather than purchasing a locally registered product.
The named-patient mechanism allows a Saudi consultant and dispensing hospital to coordinate import of a therapy approved by a recognised reference authority (in this case, the US FDA) when no clinically suitable locally registered alternative exists. The application is filed through SFDA's drug.sfda.gov.sa portal by the dispensing hospital's licensed pharmacist on the consultant's behalf, with the clinical rationale letter, genetic report, antibody results, and qualified-centre plan attached.
NUPCO, the National Unified Procurement Company, sits in the procurement loop for public-sector hospitals; for named-patient gene-therapy cases, NUPCO is typically not involved unless your son's care plan is at a NUPCO-contracted public hospital and his case is being underwritten by Vision 2030 or MoH funding.
Typical SFDA approval timing on a complete, well-documented file is four to eight weeks. Complex cases (hepatic complexity, antibody-borderline serology) can extend longer.
In the kingdom, the qualified-centre options for paediatric AAV gene therapy administration are clustered in the tertiary research hospitals. King Faisal Specialist Hospital and Research Centre, Riyadh, has the deepest demonstrated DMD clinical and research base in the country, with a paediatric neuromuscular service that has authored Saudi DMD management consensus statements; its Department of Neurosciences has led the Saudi dystrophin mutation work. King Abdulaziz Medical City under National Guard Health Affairs has comparable infrastructure and runs an active rare-disease genetics service. KFSHRC Jeddah serves the western region with the same clinical standards. For private-sector preference, Dr Sulaiman Al-Habib Medical Group's flagship Riyadh facilities can coordinate gene-therapy cases in conjunction with a Saudi consultant who holds privileges there.
Some Saudi families have travelled to the UAE for Elevidys access where the UAE timeline has been shorter and the local registration is in place. Reserve Meds can coordinate either pattern depending on what your consultant and your family prefer.
The cost conversation, in the form a Saudi family needs
The Elevidys drug price in 2026 sits in an indicative range of roughly USD 3.0 to 3.5 million, or approximately SAR 11.3 to 13.1 million, for the one-time infusion product itself. That is the manufacturer's price for the gene therapy. The full cost of care includes the pre-infusion workup we described above, the infusion-day admission, the peri-infusion immunomodulation protocol (oral corticosteroids beginning approximately one day before the infusion and tapering over weeks), the intensive monitoring schedule for the first six months, and any travel costs if the qualified centre is outside your city.
When we issue a quote at intake, we separate every line: drug, qualified-centre admission, immunomodulation drugs, monitoring labs, our coordination fee. Nothing is bundled. We do not put a markup on the manufacturer's drug price. We charge a transparent coordination fee for the case-management work, disclosed in writing before any funds move.
Insurance coverage of Elevidys in Saudi Arabia is uneven. Because Elevidys is not yet on the CCHI list, reimbursement under standard CCHI-regulated plans is not currently available. Private insurers (Bupa Arabia, Tawuniya, MedGulf, Walaa) handle one-time gene therapies on a case-by-case prior-authorisation basis, with approval uncommon outside flagship-hospital Vision 2030 pilot frameworks. We supply the prior-authorisation documentation packet to your insurer at no charge as part of the case file. We do not process insurance claims directly. Most Saudi Elevidys cases to date have proceeded as cash-pay with reimbursement, where it materialises, as a partial post-treatment offset.
For Saudi-national families being treated at KFSHRC or KAMC, your consultant will know whether any current MoH or Vision 2030 pilot framework could underwrite the case in full or in part. Worth asking explicitly.
The six months after the infusion
The peri-infusion immunomodulation protocol is intensive. Your son will be on oral corticosteroids in addition to his existing DMD steroid regimen for roughly the first eight weeks. Weekly liver function panels (AST, ALT, GGT, bilirubin) for the first three months and biweekly through month six are the published monitoring standard. Cardiac surveillance for myocarditis includes troponin checks and echocardiography per the centre's protocol. Hospitalisation for steroid-responsive hepatitis is uncommon but not rare; admission for acute liver injury, which is what the 2025 boxed warning addresses, is the safety event that the monitoring schedule is designed to catch early.
A practical implication for the family: your son's school attendance, sports participation, and social activity will be partially restricted for several weeks while the immune response is being managed. We coordinate with the family on this side of the case too, including communication with the school and arranging for any tutoring or remote-learning support if you ask.
What Reserve Meds does, and what we do not do
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For a Saudi family pursuing Elevidys, our scope is the regulatory documentation packet, the SFDA named-patient filing in collaboration with your consultant and the dispensing hospital's pharmacist, the sourcing logistics from the manufacturer's authorised US distribution through DSCSA-compliant chain of custody, cold-chain shipment to the qualified Saudi centre, and named case-lead coordination from intake to the six-month post-infusion follow-up.
Reserve Meds is not your son's prescriber. We do not practise medicine. We do not manufacture Elevidys. We do not own or operate the infusion centre. We are not your insurer. Clinical decisions stay with your paediatric neurologist and the qualified centre; we are the operational layer that turns those decisions into a coordinated case.
We work cash-pay. Our coordination fee is disclosed in writing. We will not start work without a signed engagement.
A note for families weighing this
For Muslim families thinking through the religious-ethical dimension, the Islamic bioethics consensus on disease-modifying therapies that preserve life and function is broadly permissive, and families typically consult with their religious advisors before committing. We will not pressure that conversation. Families typically take between two and six weeks from first call to readiness, with that time used for extended-family consultation, financial preparation, and religious counsel. The clinical window means we ask families to be honest with themselves about the timeline. We do not push.
What to do if you want to start
The first concrete step is a call with our case-lead so we can confirm whether Elevidys is the right consideration for your son before any documentation work begins. If your son is non-ambulatory, or under 4, or in a situation where Elevidys is not the answer, reach out anyway: we will walk through what other options exist for his specific picture.
Most families reach us first on WhatsApp, which is the medium we hold open during Saudi business hours (Sunday-Thursday) and on weekends for active cases.
Start your son's case on the portal, or open a WhatsApp conversation with the case-lead and we will take it from there.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating paediatric neurologist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.
Regulatory status of Elevidys in Saudi Arabia, 2026
Elevidys (delandistrogene moxeparvovec-rokl) is not currently held on the locally registered medicines list of the Saudi Food and Drug Authority (SFDA). The product is approved by the US Food and Drug Administration per the labelled indication of ambulatory and non-ambulatory patients aged 4 years and older with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene (see the FDA label at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu).
Because Elevidys is not on the SFDA locally registered list, access for a Saudi Arabia-based patient runs through the named-patient and personal-import framework that the SFDA maintains for reference-authority-approved medicines that are not held locally. The official SFDA portal is at www.sfda.gov.sa/en. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies); no locally available alternative is clinically equivalent for the specific patient indication; the treating physician of record takes documented clinical responsibility; and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility.
The named-patient and personal-import pathway is the routine framework. For a complex cell or gene therapy that requires a US-certified treatment center, the practical route is patient travel to that certified center rather than import into Saudi Arabia; see Block 2 below for the operational shape on that case type.
Tertiary centers and clinical coordination in Saudi Arabia
The Saudi Arabia tertiary referral network for a Elevidys case is concentrated at King Faisal Specialist Hospital and Research Centre (KFSHRC), King Abdulaziz Medical City (KAMC), and King Fahad Medical City (KFMC). These centers carry the haematology, oncology, paediatric subspecialty, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For cellular and gene therapies that require leukapheresis collection, AAV infusion, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For cell and gene therapies specifically, the practical access pathway runs through patient travel to a US-certified treatment center (Casgevy authorised treatment centers, Yescarta certified centers, Abecma certified centers, Zolgensma certified centers, Elevidys treatment centers, Hemgenix treatment centers, and so on) rather than import of the cellular or AAV product into Saudi Arabia. The tertiary Saudi Arabia centers handle the upstream referral package assembly (clinical summary, pathology, imaging, organ function panel, infectious disease screen, performance status), the US-side coordination, and the long-term follow-up after the patient returns home. Reserve Meds coordinates the cross-border arc between the Saudi Arabia tertiary team and the US treatment center, including travel and accommodation logistics, financial clearance, and post-treatment data flow.
For oral kinase inhibitors and antibody therapies that can be administered in Saudi Arabia once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule.
Saudi Arabia pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once your treating physician's documentation is in. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only range for Elevidys sits at approximately USD 3,200,000 to USD 3,300,000 per one-time AAV gene therapy infusion (US wholesale acquisition cost). In SAR terms at the 2026 reference rate of 1 USD = 3.750 SAR, that translates to a drug-only band of approximately SAR 12,000,000 to SAR 12,375,000.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, US treatment center facility and physician fees where applicable (for cellular and gene therapies, the facility cost commonly equals or exceeds the product cost), Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a cell or gene therapy case the total course cost in 2026 commonly lands at 1.5x to 2.5x the drug-only band once US treatment center fees, lymphodepletion or pre-infusion conditioning, inpatient monitoring, complication management, and family travel and accommodation are added in.
Payer posture in Saudi Arabia is overwhelmingly cash-pay for named-patient imports and cross-border CAR-T cases. Public coverage (CCHI essential drug list at https://www.cchi.gov.sa) generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Elevidys case in Saudi Arabia are: (1) Regulatory documentation complexity. The SFDA named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format SFDA reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Elevidys from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) For cell and gene therapies, the US-certified treatment center qualification gate. Casgevy, Yescarta, Carvykti, Abecma, Zolgensma, Elevidys, Hemgenix, and Luxturna can only be administered at a manufacturer-certified treatment center. Reserve Meds maintains the referral arcs to the appropriate US-certified centers and handles the referral package routing, financial clearance, and the multi-week stay coordination. (4) Family logistics. Patient and caregiver travel, accommodation near the treatment center, in-US transport, translator support where needed, and post-treatment data flow back to the treating Saudi Arabia physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Elevidys: the labelled indication is ambulatory and non-ambulatory patients aged 4 years and older with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene. The relevant clinical-practice guideline body is Parent Project Muscular Dystrophy clinical care guidelines at www.parentprojectmd.org. Your treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Elevidys in Saudi Arabia, 2026
The Saudi Food and Drug Authority (SFDA) portal at www.sfda.gov.sa/en has not posted a Elevidys-specific listing on the publicly searchable locally registered medicines list at www.sfda.gov.sa/en/drugs-list as of 2026-06-04. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages have not registered a Elevidys-specific safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication remains ambulatory and non-ambulatory patients aged 4 years and older with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene (see the current label at accessdata.fda.gov). Sarepta Therapeutics continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The Parent Project Muscular Dystrophy clinical care guidelines guidance at www.parentprojectmd.org remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.